Seroquel Clinical Trials

Browse 16 Seroquel Medical Studies Across 96 Cities

2 Phase 3 Trial ยท 120 Seroquel Clinics

Clinical TrialsSeroquel Clinical Trials
Reviewed by Michael Gill, B. Sc.
Image of University of Ottawa, Institute of Mental Health Research in Ottawa, Canada.

Seroquel/Teva-Quetiapinefor Healthy Subjects

18 - 50
Male
Ottawa, Canada
Generic describes a pharmaceutical product that does not have a brand name or trademark. Generic medications should be the equivalent of brand medications. Only their price should be different. The active ingredient of the generic medication has to be within a window of 80 to 125% of the original in the blood. There are reports that this standard is not always followed after the medication has been on the market. Indeed, it was observed that some patients previously stable on original medications relapsed when switched to a generic. Several factors could account for this problem. Such problems have been reported for Pindolol, Quetiapine, and Trazodone. Some properties of specific brands of the generics and the original brands will be examined for these three medications. The three original medications used in this study are the Visken, the Seroquel, and the Desyrel. The three generics are the Teva-pindolol, the Teva-Quetiapine, and the Teva-Trazodone. They are all available on the Canadian market by prescription.
Phase 1
Waitlist Available
University of Ottawa, Institute of Mental Health ResearchPierre Blier, MD, PhD
10 Seroquel Clinical Trials Near Me
Top Cities for Seroquel Clinical Trials
Image of San Antonio in Texas.
San Antonio
3Active Trials
UT Health Science Center - San AntonioTop Active Site
Image of Atlanta in Georgia.
Atlanta
3Active Trials
Advanced Discovery Research LLCTop Active Site
Seroquel Clinical Trials by Phase of Trial
N/A Seroquel Clinical Trials
3Active Seroquel Clinical Trials
2Number of Unique Treatments
3Number of Active Locations
InterventionTreatmentTreatment
Most Recent Seroquel Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Clozapine Arm for Schizophrenia
8/16/2023
Phase 4
SEP-363856 for Schizophrenia
11/15/2022
Phase 1
Quetiapine for Parkinson's Disease
10/24/2022
Phase 4
SEP-363856 for Schizophrenia
6/13/2022
Phase 1
quetiapine for Dementia
4/22/2022
Phase 4

Seroquel is an atypical antipsychotic medication that is currently approved for the treatment of schizophrenia and acute manic episodes in patients with Bipolar disorder.

It's also occasionally prescribed as an adjunct treatment for patients with major depressive disorder. However, Seroquel is currently being studied as a potential treatment for several other disorders.

What are Seroquel Clinical Trials?

Seroquel has already been found to benefit patients with schizophrenia and bipolar mania, but its safety and effectiveness in the treatment of teenagers continues to be studied.

Researchers are also still trying to determine whether Seroquel works better alone or in conjunction with Lithium in patients who are diagnosed with Bipolar Disorder and if the medication is truly beneficial for those suffering from Major Depressive Disorder.

Why is Seroquel Being Studied in Clinical Trials?

Seroquel is still being studied in clinical trials to determine if it can be used to effectively treat conditions beyond schizophrenia and if it's a safe option for adolescent patients.

Although Seroquel is already being prescribed off-label for the treatment of Major Depression, it has not yet been found to be an effective treatment for this condition, which is why further studies are needed.

Atypical antipsychotics, such as Seroquel, have been found to help patients with Bipolar Disorder, but it's still unclear as to whether they can work alone or need to be prescribed as a combined treatment.

Additionally, Seroquel is currently being studied as a possible remedy for heavy alcohol consumption. If Seroquel is found to be effective at reducing heavy drinking, it could be a revolutionary treatment for alcoholism.

How Does Seroquel Treatment Work?

Seroquel affects the release of certain neurotransmitters in the brain that regulate thoughts and mood.

Schizophrenia has been associated with overactivity of dopamine in the brain. Seroquel works by inhibiting the release of this neurotransmitter, thereby reducing delusions, hallucinations, and mania.

Seroquel also impacts the release of serotonin, which is the neurotransmitter that regulates mood, which explains its reported effectiveness for the treatment of mood disorders, such as Bipolar Disorder and Major Depressive Disorder.

What are Some of the Breakthrough Clinical trials Involving Seroquel?

The most notable Seroquel breakthrough study is the 2007 published and peer reviewed study on the tolerability and effectiveness of the medication in patients with Schizophrenia.

The study found that most patients experienced a reduction in symptoms of psychosis with far fewer side effects than traditional antipsychotic medications, such as Haldol.

This study was especially important because before the development of atypical antipsychotic medication, patients with schizophrenia were prescribed heavy duty medications with major long-term adverse effects, including Tardive Dyskinesia.

Who are the Key Opinion Leaders on Seroquel Clinical Trials Research?

Although AstraZeneca hasn't published the names of the key opinion leaders in Seroquel research, these leaders have still played a vital role in Seroquel's availability to the public for the treatment of mental disorders.

Several key opinion leaders have openly supported Seroquel being marketed to physicians and the public, which has resulted in more interest in this innovative medication.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: August 17th, 2023

References1 Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, Brummel NE, Hughes CG, Vasilevskis EE, Shintani AK, Moons KG, Geevarghese SK, Canonico A, Hopkins RO, Bernard GR, Dittus RS, Ely EW; BRAIN-ICU Study Investigators. Long-term cognitive impairment after critical illness. N Engl J Med. 2013 Oct 3;369(14):1306-16. doi: 10.1056/NEJMoa1301372. https://pubmed.ncbi.nlm.nih.gov/240880922 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x. https://pubmed.ncbi.nlm.nih.gov/68808203 Devlin JW, Skrobik Y, Gelinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299. https://pubmed.ncbi.nlm.nih.gov/301133794 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. https://pubmed.ncbi.nlm.nih.gov/68808205 Devlin JW, Skrobik Y, Gรฉlinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299. https://pubmed.ncbi.nlm.nih.gov/301133796 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. https://pubmed.ncbi.nlm.nih.gov/15939147 Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum In: J Am Geriatr Soc. 2019 Sep;67(9):1991. https://pubmed.ncbi.nlm.nih.gov/158170198 Nasreddine ZS, Phillips NA, Bรฉdirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991. https://pubmed.ncbi.nlm.nih.gov/158170199 Richards KC, O'Sullivan PS, Phillips RL. Measurement of sleep in critically ill patients. J Nurs Meas. 2000 Fall-Winter;8(2):131-44. https://pubmed.ncbi.nlm.nih.gov/1122758010 Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, Inouye SK, Bernard GR, Dittus RS. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 Apr 14;291(14):1753-62. https://pubmed.ncbi.nlm.nih.gov/15082703
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top